Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
NEW ORLEANS, Jan. 25, 2016 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 22, 2016 to file lead plaintiff applications in a securities class action lawsuit against HeartWare International Inc. (Nasdaq:HTWR), if they purchased the Company’s securities between June 10, 2014 and January 11, 2016, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
What You May Do
If you purchased shares of HeartWare and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 22, 2016.
About the Lawsuit
HeartWare and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On September 9, 2015, HeartWare disclosed that it was halting enrollment in the trial for MVAD, a pump that it was developing, because of a manufacturing problem. Thereafter, on October 12, 2015, HeartWare disclosed that patients had suffered adverse events and the trial would be further delayed. Finally, on January 11, 2016, HeartWare revealed that approximately half of the patients implanted with the MVAD experienced serious adverse events and the trial would be delayed indefinitely. Following these announcements, the price of HeartWare's stock plummeted.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
